Skip to main content
Clinical Trials/IRCT20201219049763N1
IRCT20201219049763N1
Recruiting
Phase 3

A clinical trial to assess the effectiveness of antiemetic and anti-halitosis topical peppermint cream and orally ingestible peppermint oxymel mouthwash in breast cancer patients during chemotherapy

Iranian academic center for education culture and research0 sites225 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Breast cancer patients treated with chemotherapy drugs.
Sponsor
Iranian academic center for education culture and research
Enrollment
225
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Iranian academic center for education culture and research

Eligibility Criteria

Inclusion Criteria

  • No history of nausea and vomiting for other reasons
  • Full consciousness
  • Complete satisfaction in participating in this project
  • Breast cancer, ac4T4 chemotherapy regimen, taking anti\-nausea and vomiting drugs Aprepitant and Dexamethasone
  • No history of allergies Medicinal plants
  • No history of respiratory diseases, asthma, diabetes and autoimmune diseases

Exclusion Criteria

  • Eliminate patients who use medications or treatments other than those prescribed during the study to reduce nausea and vomiting
  • Patients who forget to use the product and mouthwash three or more times in a row

Outcomes

Primary Outcomes

Not specified

Similar Trials